Long Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) updated investors Thursday morning on both its Zerenex development program and its 3Q financials, reiterating that pivotal Phase 3 data for the … Continue Reading
Read nowLong Ideas - Orexigen Therapeutics (NASDAQ:OREX) will be releasing its third quarter earnings report after the market’s close Wednesday night, and with all of the hoopla surrounding obesity … Continue Reading
Read nowLong Ideas - On the heels of ponatinib’s Priority Review announcement, Ariad Pharmaceuticals (NASDAQ:ARIA) reported 3Q financial results Wednesday, and on its related conference call emphasized the preparation … Continue Reading
Read nowQuick Picks - Acadia Pharmaceuticals (NASDAQ:ACAD) announced its 3Q financial results Monday, reiterating the expectation for top-line pimavanserin data by the end of the month and reporting the … Continue Reading
Read nowLong Ideas - In one of Monday’s notable volume abnormalities, shares of Pharmacyclics (NASDAQ:PCYC) have exchanged hands at more than five times average volume, and PCYC is down … Continue Reading
Read nowLong Ideas - As expected, the FDA will require Ventrus Biosciences (NASDAQ:VTUS) to complete a second Phase III study of diltiazem hydrochloride cream (VEN-307) before submitting a New … Continue Reading
Read nowMost Popular - Hepatitis C drug developers have been swiftly moving towards interferon-free, oral regimens, and while Vertex’s (NASDAQ:VRTX) Incivek was briefly the lead treatment in the field, … Continue Reading
Read now